Stock Ratings / Health Care / ACXP / insiders

ALZN (35) SKYE (35) XCUR (32) SCNX (28) ⌘ Pro Terminal →

Acurx Pharmaceuticals Inc. (ACXP) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.04 -2.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.03

Acurx Pharmaceuticals Inc. (ACXP) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $5.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACXP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.04 (-2.80% 1D, market cap $5.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACXP ranks #762 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACXP compare to ALZN and SKYE in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACXP carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M) and SKYE (Skye Bioscience Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, ACXP leads on earnings multiple (N/A) while ACXP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACXP?

▼

Per ACXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736243), Acurx Pharmaceuticals Inc. generated $0 in revenue, -$8.0M in net income, and -$6.8M in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.03 (-0.69%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACXP)Realized 20D OHLCV Swing Band: ±9.8%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY ACXP SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.28-10.9% Next Q

Q2 (-2Q)

Grade E$1.14-4.4% Next Q

Q3 (-1Q)

Grade E$1.09-4.6% Next Q

Current

Grade E$1.04-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACXP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACXP currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.29) and Max Pain ($1.09) forces dealer call-delta covering toward $7.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACXP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACXP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ACXP Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ACXP)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ACXP. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACXP)

✓Walkthrough of ACXP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACXP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.17%🛡️ HOLDING TREND SUPPORT

2026-11-02O $1.07H $1.07L $1.04C $1.04VOL 64.6K

RES: $1.45SUP: $0.96SMA50: $1.29SMA200: $1.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACXP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACXP Butterfly Map → + Track ACXP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACXP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACXP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACXP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACXP)

Health Care Rank #762 of 1016 ⚔️ ALZN vs ACXP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACXP vs. ALZN, SKYE, XCUR, SCNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Acurx Pharmaceuticals Inc. (ACXP) ranks #762 by composite RQD confidence (33/100, grade E) and #929 by equity capitalization ($5.9M). Within this direct 5-issuer industry benchmark cohort, ACXP leads on earnings valuation at N/A trailing P/E, while ACXP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALZN currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with ACXP at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACXP ACTIVE Acurx Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	-2.80%	$5.9M	Benchmark Subject
ALZN Alzamend Neuro Inc.	D-	35/100	—	—	-35.0%	-0.82%	$5.9M	/alzn-vs-acxp →
SKYE Skye Bioscience Inc.	D-	35/100	—	—	-35.0%	-2.29%	$5.8M	/skye-vs-acxp →
XCUR Exicure Inc.	E	32/100	—	—	-35.0%	+8.05%	$6.1M	/xcur-vs-acxp →
SCNX Scienture Holdings Inc.	E	28/100	—	76.8%	-35.0%	-7.74%	$5.7M	/scnx-vs-acxp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001736243

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acurx Pharmaceuticals Inc. (ACXP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.0M, operating cash flow of -$6.8M, and free cash flow of -$6.8M (+34.6% YoY). On the balance sheet, ACXP closed FY2025 with $7.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$8.0M	-$6.8M	-$6.8M	$7.7M	—
FY2024 (FY)	2024-12-31	$0	-$14.1M	-$10.4M	-$10.4M	$3.9M	—
FY2023 (FY)	2023-12-31	$0	-$14.6M	-$9.8M	-$9.8M	—	—

3. ACXP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ACXP compare to ALZN and SKYE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ACXP?

Where is ACXP trading relative to its 50-day, 200-day, and 52-week technical levels?

ACXP last traded at $1.04 (-2.80% on volume of 63,198 shares), positioning the stock -19.38% below its 50-day simple moving average ($1.29) and -47.21% below its 200-day simple moving average ($1.97). Across its 52-week range of $1.03 to $7.54, ACXP sits at the 0.2% percentile with a 14-day RSI of 33.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($1.00 to $1.14).

ACXP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ACXP insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ACXP leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ACXP RQD Cockpit ACXP 12M Forecast ACXP Earnings & Move ACXP Dividends & DRIP ACXP Insiders & 13F ACXP Whale Options ACXP Profit Sankey ACXP News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ACXP — Acurx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:52:52Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ACXP scores 33 out of 100, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine 6/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow 3/20 (institutional accumulation and options positioning); Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 9/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and institutional/insider signals. A -35% ROIC and 0% FCF yield indicate the business is not currently generating returns on capital or free cash flow, so any valuation rests on future outcomes rather than present cash generation. The Piotroski F-Score of 2/9 signals weak fundamental health across the nine checks, while the Altman Z of 2.5 and Debt/Equity of 0.5 are the relatively steadier elements of the forensic picture. The low whale and insider scores mean the source data shows little evidence of conviction from large holders or insiders to offset these concerns. Upside would depend on a catalyst that changes the cash-generation picture; the data contains no such evidence, so the rating reflects present forensic risk rather than a forecast.

Business

Acurx Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $0.0B on a rounded basis, with the market data showing $5.9M. The source data does not describe specific products, customers, or revenue model. Reported revenue is $0.0M across the periods provided, indicating no revenue recognition in those years.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-8.1M	$-8.0M	N/A	$-6.8M	N/A	N/A
FY 2024	$0.0M	$-14.1M	$-14.1M	N/A	$-10.4M	N/A	N/A
FY 2023	$0.0M	$0.0M	$-14.6M	N/A	$-9.8M	N/A	N/A

Per the SEC financials, net losses narrowed from $-14.6M (FY 2023) to $-14.1M (FY 2024) to $-8.0M (FY 2025), and free cash flow moved from $-9.8M to $-10.4M to $-6.8M over the same span. Gross, operating, and net margins are reported as 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Cash and debt balances are not available in source data.

Recent Catalysts & News Wire Analysis

Per the news wire, the company is scheduled to discuss third-quarter results on Nov. 12, before market open (flagged YELLOW, market wire).
Per the news wire, a 12-month series with New to The Street on its antibiotics story was reported (YELLOW, market wire).
Per the news wire, the company lowered its quorum requirement for shareholder meetings (YELLOW, market wire).
Per the news wire, shares were reported edging up 1.60% to $1.27 while holding above a key support level (YELLOW, market wire). This figure differs from the $1.07 price in the market data and is reported as the news source states it.
Per the news wire, an item characterized as a Q2 2026 earnings report describes a wider-than-expected loss for a pre-revenue biotech (flagged RED, risk watch).
Butterfly Supply-Chain Graph: no supply-chain links or proprietary signals are recorded.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations beyond the stated Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification. The one second-order consideration the data supports is that a pre-revenue profile with negative cash flow implies dependence on external funding, but the source data does not specify financing sources or terms. Watch for the Nov. 12 results release as the next data point on the loss trajectory.

Open Questions

What are the company's cash, short-term investment, and debt balances? The financials show these as N/A.
What products or clinical programs drive the business, and what are their development stages?
What is the reconciled share price, given the $1.07 market price versus the $1.27 cited in the news wire?
What is the company's cash runway relative to its negative free cash flow?
What were the drivers of the Q2 2026 loss described as wider than expected?

ACXP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Acurx Pharmaceuticals Inc. (ACXP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACXP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 14h ago

Acurx Pharmaceuticals, Inc. (ACXP) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 17h ago

Before markets open, Acurx will discuss its third-quarter results Nov. 12.

Stock Titan report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 20h ago

Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street

Yahoo Finance report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com South Africa • 23h ago

Acurx Pharmaceuticals lowers quorum requirement for shareholder meetings By Investing.com

Investing.com South Africa report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Acurx Pharmaceuticals (ACXP) Edges Up 1.60% to $1.27 as Shares Hold Above Key Support - Stock Analysis

https://www.siam.in/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

ACXP Q2 2026 Earnings: Wider-Than-Expected Loss Pressures Pre-Revenue Biotech - Forward EPS Estimate

https://www.dars.gov.et/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Acurx (ACXP) Stock Screener: -5.98% Decline on Elevated Volume 2026-10-16 - Extension Target

https://www.siam.in/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

ACXP Q2 2026 Earnings: Wider-Than-Expected Loss per Share Despite a Modest Stock Gain - Earnings Manipulation Risk

https://www.dars.gov.et/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACXP Bull vs. Bear Conversation Board — What's Your Call at $1.04?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACXP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.94 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ACXP (E • RQD 33/100) a Buy at $1.07?

Welcome to the ACXP (Acurx Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.85 (-20.6%)

Spot @ $1.07

Pump the brakes on ACXP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ACXP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Acurx Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.27 (+18.7%)

Spot @ $1.07

ACXP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ACXP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.07 (52-wk range $1.03 - $7.54), any beat on forward guidance forces shorts and underweight funds to chase.